ProtAffin Biotechnologie AG
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From ProtAffin Biotechnologie AG
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a comprehensive monthly review of emerging life science companies that have received venture funding, including companies within the In Vitro Diagnostics, Medical Devices, and Pharmaceuticals sectors. This month’s column covers deals announced May through June.
Derived from Strategic Transactions, a premium source for tracking life sciences deal activity, the Venture Funding Deals column provides a monthly review of emerging In Vitro Diagnostic, Medical Device, and Pharmaceutical companies that have received venture funding. This month’s column covers deals announced September through October 2014.
The unique industrial collaboration with University College London will exploit in-depth knowledge of blood-flow biology to develop new products for CV disease, fetal growth retardation and melanoma.
ProtAffin has begun clinical testing of its lead product candidate, the anti-inflammatory PA401AG, a modified form of the human chemokine IL-8.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.